Michael Zachareas, MD
Urology · Beverly, MANPI 1528000254
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $21,429 of the $26,870 with a category attached, or 79.7%. It is spread thinly across 47 manufacturers, the largest accounting for just 14.4% — the pattern of someone who eats at a lot of different presentations. Among urology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 892 payments — averaging $30.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Ferring Pharmaceuticals Inc.$3K
- Axonics, Inc.$3K
- Teleflex LLC$2K
- Astellas Pharma US Inc$2K
- Neotract Inc.$2K
- plus $11K from 41 others
What the payments were for
- Consulting fees$2,1738%
- Speaking & faculty fees$2051%
- Travel & lodging$2,1268%
- Food & beverage$21,42980%
- Education$9383%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADSTILADRIN$2,471
- INTERSTIM$2,274
- Axonics r-SNM System$1,181
- UroLift$811
- Axonics$804
- UroLift System$467
- CAMCEVI$144
- CVAC Aspiration System$119
How this compares
$26,870 in reported general payments places this provider in the 90th percentile of 327 urology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 60 | $59,476 |
| MyrbetriqMirabegron | 53 | $53,840 |
| Mirabegron ErMirabegron | 14 | $8,284 |
| XyostedTestosterone Enanthate | 13 | $7,959 |
| Tamsulosin Hcl | 299 | $4,796 |
| Potassium Citrate ErPotassium Citrate | 60 | $3,775 |
| Finasteride | 222 | $3,769 |
| Testosterone | 23 | $2,362 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 70 | $2,323 |
| Oxybutynin Chloride ErOxybutynin Chloride | 61 | $2,067 |
| Methenamine Hippurate | 23 | $1,843 |
| Anastrozole | 118 | $592 |
| Testosterone Cypionate | 30 | $555 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 25 | $356 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 96 | $317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $258 | $59,47660 claims |
| Astellas Pharma US IncMyrbetriq | $2,054 | $53,84053 claims |
| Antares Pharma, Inc.Xyosted | $1,251 | $7,95913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 327 urology providers in Massachusetts.
Other urology in Beverly
- Christopher CutieBoston$3.5M
- Brian EisnerBoston$424K
- David StaskinBrighton$407K
- Liam HurleyNorth Andover$319K
- Stephen DretlerBoston$298K
- Abraham MorgentalerChestnut Hill$290K
- Louis LiouCambridge$278K
- Tony LuongoBoston$265K
- Ricardo MunarrizBoston$118K
- Andrew KramerHyannis$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.